financetom
Business
financetom
/
Business
/
Market Chatter: Blue Owl Explores Partial Sale of Fund Backing Clearlake, Golub
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Blue Owl Explores Partial Sale of Fund Backing Clearlake, Golub
Feb 25, 2025 10:21 AM

01:01 PM EST, 02/25/2025 (MT Newswires) -- Blue Owl Capital (OWL) is exploring a sale of a portion of a fund that owns minority stakes in Clearlake Capital Group, I Squared Capital and Golub Capital, Bloomberg reported Tuesday, citing people with knowledge of the matter.

Blue Owl did not immediately reply to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 21.32, Change: -0.45, Percent Change: -2.07

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arcadium Lithium Earnings Can Triple By FY26 Despite Weak EV Demand: Analyst
Arcadium Lithium Earnings Can Triple By FY26 Despite Weak EV Demand: Analyst
Jun 26, 2024
Arcadium Lithium plc ( ARLTF ) shares are trading higher today. RBC Capital analyst Kaan Peker initiated coverage on the stock with an Outperform rating and a price target of $4.00. The analyst writes that Arcadium, formed by the recent merger of Allkem and Livent, offers investors highly integrated and diversified exposure to lithium and chemicals. The analyst says the...
Moderna RSV Shot Efficacy Lower Than Rivals' Vaccines, CDC Data Shows
Moderna RSV Shot Efficacy Lower Than Rivals' Vaccines, CDC Data Shows
Jun 26, 2024
02:57 PM EDT, 06/26/2024 (MT Newswires) -- The efficacy of Moderna's ( MRNA ) RSV vaccine drops sharply in the second year and is lower than that of rival vaccines, according to the Centers for Disease Control and Prevention. Moderna's ( MRNA ) RSV shot dropped from 55% efficacy over the first 12 months to 36% in year two in...
Update: Citigroup Head of Risk Data, Analytics Leaves
Update: Citigroup Head of Risk Data, Analytics Leaves
Jun 26, 2024
02:55 PM EDT, 06/26/2024 (MT Newswires) -- (Adds confirmation from the company in the first and the second paragraphs). Citigroup's ( C ) global head of risk data, analytics, reporting and technology left the financial services firm earlier this week, a Citigroup ( C ) spokesperson told MT Newswires on Wednesday. The spokesperson declined to provide additional details. Peter Cai...
Fox to Maintain Current Trends in Q4, 'Cyclical Tailwinds' to Accelerate Growth in Fiscal 2025, UBS Says
Fox to Maintain Current Trends in Q4, 'Cyclical Tailwinds' to Accelerate Growth in Fiscal 2025, UBS Says
Jun 26, 2024
03:00 PM EDT, 06/26/2024 (MT Newswires) -- Fox (FOX, FOXA) will see ongoing trends continue in fiscal Q4 followed by cyclical tailwinds that will accelerate growth in fiscal 2025, UBS said in an emailed note to clients Wednesday. The investment firm said Fox's flat advertising revenue, soft performance and challenges in the entertainment sector were offset by strong sports spending...
Copyright 2023-2026 - www.financetom.com All Rights Reserved